Literature DB >> 8994707

Intraarterial pressure gradients after randomized angioplasty or stenting of iliac artery lesions. Dutch Iliac Stent Trial Study Group.

E Tetteroo1, C Haaring, Y van der Graaf, J P van Schaik, A D van Engelen, W P Mali.   

Abstract

PURPOSE: To determine initial technical results of percutaneous transluminal angioplasty (PTA) and stent procedures in the iliac artery, mean intraarterial pressure gradients were recorded before and after each procedure.
METHODS: We randomly assigned 213 patients with typical intermittent claudication to primary stent placement (n = 107) or primary PTA (n = 106), with subsequent stenting in the case of a residual mean pressure gradient of > 10 mmHg (n = 45). Eligibility criteria included angiographic iliac artery stenosis (> 50% diameter reduction) and/or a peak systolic velocity ratio > 2.5 on duplex examination. Mean intraarterial pressures were simultaneously recorded above and below the lesion, at rest and also during vasodilatation in the case of a resting gradient < or = 10 mmHg.
RESULTS: Pressure gradients in the primary stent group were 14.9 +/- 10.4 mmHg before and 2.9 +/- 3.5 mmHg after stenting. Pressure gradients in the primary PTA group were 17.3 +/- 11.3 mmHg pre-PTA, 4.2 +/- 5.4 mmHg post-PTA, and 2.5 +/- 2.8 mmHg after selective stenting. Compared with primary stent placement, PTA plus selective stent placement avoided application of a stent in 63% (86/137) of cases, resulting in a considerable cost saving.
CONCLUSION: Technical results of primary stenting and PTA plus selective stenting are similar in terms of residual pressure gradients.

Entities:  

Mesh:

Year:  1996        PMID: 8994707     DOI: 10.1007/bf02577629

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  30 in total

1.  Stenting of the iliac arteries with the Palmaz stent: experience from a multicenter trial.

Authors:  J C Palmaz; J C Laborde; F J Rivera; C E Encarnacion; J D Lutz; J G Moss
Journal:  Cardiovasc Intervent Radiol       Date:  1992 Sep-Oct       Impact factor: 2.740

2.  Aortoiliac stenosis; diagnostic significance of vascular hemodynamics.

Authors:  H HAIMOVICI; D J ESCHER
Journal:  AMA Arch Surg       Date:  1956-01

Review 3.  Intravascular stents. Status of development and clinical application.

Authors:  B T Katzen; G J Becker
Journal:  Surg Clin North Am       Date:  1992-08       Impact factor: 2.741

4.  Standards for evaluating results of interventional therapy for peripheral vascular disease.

Authors:  R B Rutherford
Journal:  Circulation       Date:  1991-02       Impact factor: 29.690

5.  Multiple subcritical arterial stenoses: effect on poststenotic pressure and flow.

Authors:  D P Flanigan; J P Tullis; V L Streeter; W M Whitehouse; W J Fry; J C Stanley
Journal:  Ann Surg       Date:  1977-11       Impact factor: 12.969

6.  Assessment of aortoiliac disease using hemodynamic measures.

Authors:  P J Breslau; P J Jörning; J M Greep
Journal:  Arch Surg       Date:  1985-09

7.  Aortic and iliac stenoses: follow-up results of stent placement after insufficient balloon angioplasty in 118 cases.

Authors:  D Vorwerk; R W Günther; K Schürmann; G Wendt
Journal:  Radiology       Date:  1996-01       Impact factor: 11.105

8.  Palmaz vascular stent: initial clinical experience.

Authors:  J Bonn; G A Gardiner; M J Shapiro; K L Sullivan; D C Levin
Journal:  Radiology       Date:  1990-03       Impact factor: 11.105

9.  Aortofemoral or femoropopliteal revascularization? A prospective evaluation of the papaverine test.

Authors:  D P Flanigan; T J Ryan; L R Williams; J A Schwartz; B Gray; J J Schuler
Journal:  J Vasc Surg       Date:  1984-01       Impact factor: 4.268

10.  Analysis and comparison of pressure gradients and ratios for predicting iliac stenosis.

Authors:  J P Archie
Journal:  Ann Vasc Surg       Date:  1994-05       Impact factor: 1.466

View more
  10 in total

1.  Comparison of the Health Utilities Index Mark 3 (HUI3) and the EuroQol EQ-5D in patients treated for intermittent claudication.

Authors:  J L Bosch; M G Hunink
Journal:  Qual Life Res       Date:  2000       Impact factor: 4.147

2.  Vascular Physics: Explaining the Nature of Escape Veins and When to Use Endovascular Ligation.

Authors:  Taylor S Harmon; James Cunningham; Abdur R Khan; Erik Soule; Jerry Matteo
Journal:  Cureus       Date:  2018-09-24

3.  Pressure Measurements across Vascular Stenoses. Practice and Pitfalls.

Authors:  S G Imbesi; C W Kerber
Journal:  Interv Neuroradiol       Date:  2001-05-15       Impact factor: 1.610

4.  Endovascular management of aortoiliac occlusive disease.

Authors:  Melissa J Neisen
Journal:  Semin Intervent Radiol       Date:  2009-12       Impact factor: 1.513

Review 5.  Peripheral artery disease. Part 2: medical and endovascular treatment.

Authors:  Mitchell D Weinberg; Joe F Lau; Kenneth Rosenfield; Jeffrey W Olin
Journal:  Nat Rev Cardiol       Date:  2011-06-14       Impact factor: 32.419

6.  Physiologic and anatomic assessment of a canine carotid artery stenosis model utilizing phase contrast with vastly undersampled isotropic projection imaging.

Authors:  A S Turk; K M Johnson; D Lum; D Niemann; B Aagaard-Kienitz; D Consigny; J Grinde; P Turski; V Haughton; C Mistretta
Journal:  AJNR Am J Neuroradiol       Date:  2007-01       Impact factor: 3.825

7.  Angioplasty versus stenting for iliac artery lesions.

Authors:  Hidde Jongsma; Joost Bekken; Ninos Ayez; Cornelis J Hoogewerf; Vincent Van Weel; Bram Fioole
Journal:  Cochrane Database Syst Rev       Date:  2020-12-01

8.  Stenting for peripheral artery disease of the lower extremities: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2010-09-01

Review 9.  Endovascular stents for intermittent claudication.

Authors:  Paul Bachoo; P A Thorpe; Heather Maxwell; Karen Welch
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

Review 10.  Optimal management of renal artery fibromuscular dysplasia.

Authors:  Anders Gottsäter; Bengt Lindblad
Journal:  Ther Clin Risk Manag       Date:  2014-07-28       Impact factor: 2.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.